3/22
01:11 am
rxrx
Recursion Pharmaceuticals Details AI-Driven Drug Pipeline, Sanofi/Roche Milestones, Runway to 2028 [Yahoo! Finance]
Low
Report
Recursion Pharmaceuticals Details AI-Driven Drug Pipeline, Sanofi/Roche Milestones, Runway to 2028 [Yahoo! Finance]
3/13
08:04 pm
rxrx
Jim Cramer on Recursion Pharmaceuticals: “It's a Let Down, Big Let Down” [Yahoo! Finance]
Low
Report
Jim Cramer on Recursion Pharmaceuticals: “It's a Let Down, Big Let Down” [Yahoo! Finance]
3/10
10:44 pm
rxrx
Is Recursion Pharmaceuticals (RXRX) Pricing Reflect Recent 1-Year Share Slump Accurately [Yahoo! Finance]
Neutral
Report
Is Recursion Pharmaceuticals (RXRX) Pricing Reflect Recent 1-Year Share Slump Accurately [Yahoo! Finance]
3/9
10:36 pm
rxrx
Recursion's First AI Clinical Proof Links Pipeline Progress With Valuation Gap [Yahoo! Finance]
Low
Report
Recursion's First AI Clinical Proof Links Pipeline Progress With Valuation Gap [Yahoo! Finance]
3/9
08:36 pm
rxrx
What Makes Recursion Pharmaceuticals (RXRX) So Attractive [Yahoo! Finance]
Low
Report
What Makes Recursion Pharmaceuticals (RXRX) So Attractive [Yahoo! Finance]
3/8
12:30 pm
rxrx
Can This AI Stock Bounce Back in 2026? [Yahoo! Finance]
Low
Report
Can This AI Stock Bounce Back in 2026? [Yahoo! Finance]
3/6
12:25 pm
rxrx
BoFA Lowers PT on Recursion Pharmaceuticals (RXRX), Keeps a Hold Rating [Yahoo! Finance]
Low
Report
BoFA Lowers PT on Recursion Pharmaceuticals (RXRX), Keeps a Hold Rating [Yahoo! Finance]
3/2
04:43 pm
rxrx
Recursion: Nvidia Sells Out, Collaboration Still Alive, Data Ahead [Seeking Alpha]
Low
Report
Recursion: Nvidia Sells Out, Collaboration Still Alive, Data Ahead [Seeking Alpha]
2/28
07:02 pm
rxrx
Recursion's REC-4881 Milestone And Cash Runway Shift Risk Reward Profile [Yahoo! Finance]
Low
Report
Recursion's REC-4881 Milestone And Cash Runway Shift Risk Reward Profile [Yahoo! Finance]
2/28
01:30 am
rxrx
Low
Report
2/26
08:03 am
rxrx
Recursion Pharmaceuticals (RXRX) had its "buy" rating reaffirmed by Needham & Company LLC. They now have a $8.00 price target on the stock.
Low
Report
Recursion Pharmaceuticals (RXRX) had its "buy" rating reaffirmed by Needham & Company LLC. They now have a $8.00 price target on the stock.
2/25
05:43 pm
rxrx
Recursion Pharmaceuticals Q4 Earnings Call Highlights [Yahoo! Finance]
Low
Report
Recursion Pharmaceuticals Q4 Earnings Call Highlights [Yahoo! Finance]
2/25
03:58 pm
rxrx
Recursion Pharmaceuticals (RXRX) had its "neutral" rating reaffirmed by Bank of America Corporation.
Low
Report
Recursion Pharmaceuticals (RXRX) had its "neutral" rating reaffirmed by Bank of America Corporation.
2/25
03:22 pm
rxrx
Recursion Pharmaceuticals Q4: Why My December Buy Call Was Too Optimistic [Seeking Alpha]
Low
Report
Recursion Pharmaceuticals Q4: Why My December Buy Call Was Too Optimistic [Seeking Alpha]
2/25
01:14 pm
rxrx
Recursion (RXRX) Q4 2025 Earnings Call Transcript [Yahoo! Finance]
Low
Report
Recursion (RXRX) Q4 2025 Earnings Call Transcript [Yahoo! Finance]
2/25
01:04 pm
rxrx
Recursion Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary [Yahoo! Finance]
Low
Report
Recursion Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary [Yahoo! Finance]
2/25
06:30 am
rxrx
Recursion Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Low
Report
Recursion Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
2/23
08:00 am
rxrx
Recursion To Be Featured in HighRes’ Lightning Talk at NVIDIA GTC
Low
Report
Recursion To Be Featured in HighRes’ Lightning Talk at NVIDIA GTC
2/23
07:55 am
rxrx
Recursion to Participate in Upcoming Investor Conferences
Low
Report
Recursion to Participate in Upcoming Investor Conferences
2/18
07:40 pm
rxrx
Recursion Pharmaceuticals (RXRX) Exceeds Market Returns: Some Facts to Consider [Yahoo! Finance]
Medium
Report
Recursion Pharmaceuticals (RXRX) Exceeds Market Returns: Some Facts to Consider [Yahoo! Finance]
2/18
08:30 am
rxrx
Recursion to Report Fourth Quarter and Full Year 2025 Business Updates and Financial Results on February 25
High
Report
Recursion to Report Fourth Quarter and Full Year 2025 Business Updates and Financial Results on February 25
2/13
07:02 pm
rxrx
Assessing Recursion Pharmaceuticals (RXRX) After A 58% One-Year Share Price Decline [Yahoo! Finance]
Low
Report
Assessing Recursion Pharmaceuticals (RXRX) After A 58% One-Year Share Price Decline [Yahoo! Finance]
2/12
07:59 am
rxrx
Recursion Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules
Medium
Report
Recursion Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules
2/8
07:15 pm
rxrx
Assessing Recursion Pharmaceuticals (RXRX) Valuation As Shares Trade Below Fair Value Estimate [Yahoo! Finance]
Neutral
Report
Assessing Recursion Pharmaceuticals (RXRX) Valuation As Shares Trade Below Fair Value Estimate [Yahoo! Finance]
1/29
07:29 pm
rxrx
Recursion Pharmaceuticals (RXRX) Declines More Than Market: Some Information for Investors [Yahoo! Finance]
Low
Report
Recursion Pharmaceuticals (RXRX) Declines More Than Market: Some Information for Investors [Yahoo! Finance]